Abstract
To characterize the pharmacodynamic properties of CGP 69846A/ISIS 5132, an antisense oligodeoxynucleotide directed against the mitogenic signal transducer Raf-1 kinase, we investigated the elicited biological responses in human coronary artery smooth muscle cells. Cell exposure to CGP 69846A resulted in a reversible time- and concentration-dependent down-regulation of cellular Raf-1 gene expression and, ultimately, inhibition of cell cycle progression. The highest potencies of this compound to reduce Raf-1 mRNA and protein levels were observed after 24 and 48 hr of cell exposure, respectively, with corresponding IC50 values of approximately 100 and approximately 300 nM. Proliferation was inhibited with an IC50 value of approximately 300 nM after 72 hr. We interpreted the recovery rate of Raf-1 mRNA after cell exposure to antisense ODNs as the half-life (t1/2 approximately 50 hr) of active intracellular CGP 69846A in our cell culture system. The endogenous Raf-1 turnover half-life of approximately 30 hr, as assessed by monitoring metabolically labeled Raf-1 protein, correlated kinetically with the antisense-induced protein decay rate (50% decay in approximately 33 hr), indicating that the efficiency of CGP 69846A in decreasing R...Continue Reading
References
Sep 3, 1992·Nature·M SimonsR D Rosenberg
Jan 31, 1991·Nature·W KolchU R Rapp
Nov 24, 1995·Science·Z XiaM E Greenberg
Nov 3, 1995·The Journal of Biological Chemistry·M A BogoyevitchP H Sugden
Nov 10, 1995·The Journal of Biological Chemistry·A D LairdD Shalloway
Sep 1, 1995·Circulation Research·S M SchwartzE R O'Brien
Jun 4, 1993·Science·R W WagnerB C Froehler
Jan 1, 1995·Annual Review of Physiology·R Ross
Nov 1, 1994·Trends in Biochemical Sciences·G DaumU R Rapp
Mar 1, 1995·AJR. American Journal of Roentgenology·P M Consigny
Oct 1, 1994·Molecular and Cellular Biology·R K JaiswalG E Landreth
Oct 14, 1994·Science·H SunD Bar-Sagi
Sep 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·R MorishitaV J Dzau
May 19, 1994·The New England Journal of Medicine·G H Gibbons, V J Dzau
Apr 1, 1994·The Journal of Clinical Investigation·R MorishitaV J Dzau
Feb 1, 1994·Current Opinion in Genetics & Development·C J Marshall
Jun 2, 1994·Nature·S J LeeversC J Marshall
Jul 9, 1993·Journal of Medicinal Chemistry·J F MilliganJ C Martin
Aug 1, 1993·Genes & Development·D E QuelleC J Sherr
Dec 1, 1995·The Biochemical Journal·S T CrookeB P Monia
Mar 7, 1996·Nature·M VerheijR N Kolesnick
Feb 9, 1996·The Journal of Biological Chemistry·X WuK L Guan
Jun 1, 1996·Nature Medicine·B P MoniaD Fabbro
Aug 15, 1996·Nature·M F Tuite
Nov 15, 1996·The Biochemical Journal·C J RobinsonR Plevin
Dec 24, 1996·Proceedings of the National Academy of Sciences of the United States of America·B P MoniaD Fabbro
Mar 13, 1997·Nature·D S PeeperM E Ewen
Citations
Jul 21, 1998·Cell Research·A Yuryev, L P Wennogle
Mar 6, 2004·Oligonucleotides·Tzu-Fang LouDonald M Gray
May 31, 2002·Expert Opinion on Pharmacotherapy·Walter Kolch
Apr 18, 2002·Leukemia·J T Lee, J A McCubrey
Dec 22, 2016·PloS One·Xiulan Lai, Avner Friedman
Mar 10, 2001·Journal of Theoretical Biology·D A Fennell, F E Cotter